La recherche d’Hybrigenics Pharma a publié les articles scientifiques ci-dessous dans le domaine des protéases spécifiques de l’ubiquitine (USPs, une classe particulière de DUBs) et de leurs inhibiteurs.

• Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V, Harpon J, Battaglia V, Vivat V, Sippl W, Colland F. Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme. Chemistry & Biology, 2012, 19 (4), 467-477. PMID: 22520753

• Sippl W, Collura V, Colland F. Ubiquitin-specific proteases as cancer drug targets. Future Oncol. 2011 May; 7(5):619-32. PMID: 21568678.

• Colombo M, Vallese S, Peretto I, Jacq X, Rain JC, Colland F, Guedat P. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6; 5(4):552-8. PMID: 20186914.

• Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans. 2010 Feb; 38(Pt 1):137-43. Review. PMID: 20074048.

• Cholay M, Reverdy C, Benarous R, Colland F, Daviet L. Functional interaction between the ubiquitin-specific protease 25 and the SYK tyrosine kinase. Exp Cell Res. 2010 Feb 15; 316(4):667-75. Epub 2009 Nov 10. PMID: 19909739.

• Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J, Calabrese A, Borg-Capra C, Sippl W, Collura V, Boissy G, Rain JC, Guedat P, Delansorne R, Daviet L. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug; 8(8):2286-95. Epub 2009 Aug 11. PMID: 19671755.

• Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie. 2008 Feb; 90(2):270-83. Epub 2007 Sep 22. Review. PMID: 17961905.

• Guédat P, Colland F. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem. 2007 Nov 22; 8 Suppl 1:S14. Review. PubMed PMID: 18047738.

• Formstecher E, Reverdy C, Cholay M, Planquette C, Trouplin V, Lehrmann H, Aresta S, Calabrese A, Arar K, Daviet L, Colland F. Combination of active and inactive siRNA targeting the mitotic kinesin Eg5 impairs silencing efficiency in several cancer cell lines. Oligonucleotides. 2006 Winter;16(4):387-94. PMID: 17155913.

• Colland F. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference. IDrugs. 2006 Mar; 9(3):179-81. PMID:16523381.